KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

LATEST NEWS

Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

Jun. 4, 2018

The results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA).

Kamada Reports Financial Results for First Quarter of 2018

May. 15, 2018

Kamada today announced financial results for the three months ended
March 31, 2018.

More News

FINANCIAL REPORTS

XBRL Annual Reports 2017

Dec. 31, 2017

Annual Report 2017

Dec. 30, 2017

Q3 / 2017 Financial Report

Nov. 14, 2017

More Reports

STOCK QUOTE

NASDAQ

KMDA:$0
Change:0.00%
Date & Time:
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Chaime Orlev,
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more